tiprankstipranks
ACADIA Pharmaceuticals (GB:0A4W)
LSE:0A4W
UK Market
0A4W
ACADIA Pharmaceuticals
RESEARCH TOOLSreports

ACADIA Pharmaceuticals (0A4W) Share Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

0A4W Analyst Ratings

Strong Buy
16Ratings
Strong Buy
12 Buy
4 Hold
0 Sell
Based on 16 analysts giving stock ratings to
ACADIA
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0A4W Stock 12 Month Forecast

Average Price Target

$35.47
▲(31.99% Upside)
Based on 16 Wall Street analysts offering 12 month price targets for ACADIA Pharmaceuticals in the last 3 months. The average price target is $35.47 with a high forecast of $49.00 and a low forecast of $25.00. The average price target represents a 31.99% change from the last price of $26.87.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"17":"$17","50":"$50","25.25":"$25.3","33.5":"$33.5","41.75":"$41.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":49,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$49.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.46666666666667,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$35.47</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[17,25.25,33.5,41.75,50],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.87,28.572307692307692,30.274615384615387,31.97692307692308,33.67923076923077,35.38153846153846,37.08384615384615,38.78615384615385,40.488461538461536,42.190769230769234,43.89307692307692,45.59538461538462,47.29769230769231,{"y":49,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.87,27.53128205128205,28.192564102564102,28.853846153846156,29.515128205128207,30.176410256410257,30.837692307692308,31.49897435897436,32.16025641025641,32.821538461538466,33.48282051282052,34.14410256410257,34.80538461538462,{"y":35.46666666666667,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.87,26.726153846153846,26.582307692307694,26.43846153846154,26.294615384615387,26.15076923076923,26.006923076923076,25.863076923076925,25.71923076923077,25.575384615384614,25.431538461538462,25.287692307692307,25.143846153846155,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.62,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.62,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.62,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.62,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.62,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.87,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.87,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.87,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.87,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.87,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.87,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.87,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.87,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$49.00Average Price Target$35.47Lowest Price Target$25.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on GB:0A4W
Sean Laaman
Morgan Stanley
Morgan Stanley
$27→$28
Hold
4.21%
Upside
Assigned
08/25/26
Acadia Pharmaceuticals price target raised to $28 from $27 at Morgan StanleyAcadia Pharmaceuticals price target raised to $28 from $27 at Morgan Stanley
Deutsche Bank Analyst forecast on GB:0A4W
David Hoang
Deutsche Bank
Deutsche Bank
$37→$38
Buy
41.42%
Upside
Reiterated
08/25/26
ACADIA Pharmaceuticals (ACAD) Gets a Buy from Deutsche Bank
Citi Analyst forecast on GB:0A4W
Yigal Nochomovitz
Citi
Citi
$39→$40
Buy
48.86%
Upside
Assigned
08/25/26
Analyst Lifts ACADIA Price Target to $40 on Favorable Risk‑Reward and RADIANT Alzheimer’s Psychosis Upside
H.C. Wainwright Analyst forecast on GB:0A4W
Ananda Ghosh
H.C. Wainwright
H.C. Wainwright
$37
Buy
37.70%
Upside
Reiterated
08/25/26
ACADIA: EU Orphan Drug Launch Underscores Pricing Strength; Buy Rating and $37 Price Target Reaffirmed
BMO Capital Analyst forecast on GB:0A4W
Malcolm Hoffman
BMO Capital
BMO Capital
$36
Buy
33.98%
Upside
Reiterated
08/24/26
ACADIA: Buy Rating Reiterated as Daybue Momentum Builds and Key Pipeline Catalyst Nears; Price Target Maintained at $36
UBS Analyst forecast on GB:0A4W
Ashwani Verma
UBS
UBS
$45→$49
Buy
82.36%
Upside
Assigned
08/18/26
Acadia Pharmaceuticals price target raised to $49 from $45 at UBSAcadia Pharmaceuticals price target raised to $49 from $45 at UBS
Needham Analyst forecast on GB:0A4W
Ami Fadia
Needham
Needham
$38→$41
Buy
52.59%
Upside
Assigned
08/12/26
Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (NYSE: ELAN) and ACADIA Pharmaceuticals (NASDAQ: ACAD)
Canaccord Genuity Analyst forecast on GB:0A4W
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
$36
Buy
33.98%
Upside
Reiterated
08/12/26
ACADIA Pharmaceuticals: Buy Rating Reiterated on Undervalued Growth Story; $36 Price Target Unchanged
TD Cowen Analyst forecast on GB:0A4W
Ritu Baral
TD Cowen
TD Cowen
$37
Buy
37.70%
Upside
Assigned
08/05/26
ACADIA Pharmaceuticals: Strong Daybue Outperformance, STIX Uptake, and Raised FY26 Revenue Outlook Support Buy Rating
Citizens JMP Analyst forecast on GB:0A4W
Jason Butler
Citizens JMP
Citizens JMP
$35→$36
Buy
33.98%
Upside
Reiterated
08/05/26
Acadia Pharmaceuticals price target raised to $36 from $35 at CitizensAcadia Pharmaceuticals price target raised to $36 from $35 at Citizens
Stifel Nicolaus Analyst forecast on GB:0A4W
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$25
Hold
-6.96%
Downside
Reiterated
08/05/26
Stifel Nicolaus Sticks to Its Hold Rating for ACADIA Pharmaceuticals (ACAD)
Bank of America Securities Analyst forecast on GB:0A4W
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$30→$31
Buy
15.37%
Upside
Reiterated
08/05/26
Acadia Pharmaceuticals price target raised to $31 from $30 at BofAAcadia Pharmaceuticals price target raised to $31 from $30 at BofA
Oppenheimer Analyst forecast on GB:0A4W
Matthew Hershenhorn
Oppenheimer
Oppenheimer
$23→$25
Hold
-6.96%
Downside
Reiterated
08/05/26
Acadia Pharmaceuticals price target raised to $25 from $23 at OppenheimerAcadia Pharmaceuticals price target raised to $25 from $23 at Oppenheimer
Guggenheim Analyst forecast on GB:0A4W
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
―
Hold
―
Reiterated
08/04/26
Guggenheim Sticks to Its Hold Rating for ACADIA Pharmaceuticals (ACAD)
RBC Capital Analyst forecast on GB:0A4W
Brian Abrahams
RBC Capital
RBC Capital
$36→$37
Buy
37.70%
Upside
Assigned
08/04/26
Acadia Pharmaceuticals price target raised to $37 from $36 at RBC CapitalAcadia Pharmaceuticals price target raised to $37 from $36 at RBC Capital
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on GB:0A4W
Sean Laaman
Morgan Stanley
Morgan Stanley
$27→$28
Hold
4.21%
Upside
Assigned
08/25/26
Acadia Pharmaceuticals price target raised to $28 from $27 at Morgan StanleyAcadia Pharmaceuticals price target raised to $28 from $27 at Morgan Stanley
Deutsche Bank Analyst forecast on GB:0A4W
David Hoang
Deutsche Bank
Deutsche Bank
$37→$38
Buy
41.42%
Upside
Reiterated
08/25/26
ACADIA Pharmaceuticals (ACAD) Gets a Buy from Deutsche Bank
Citi Analyst forecast on GB:0A4W
Yigal Nochomovitz
Citi
Citi
$39→$40
Buy
48.86%
Upside
Assigned
08/25/26
Analyst Lifts ACADIA Price Target to $40 on Favorable Risk‑Reward and RADIANT Alzheimer’s Psychosis Upside
H.C. Wainwright Analyst forecast on GB:0A4W
Ananda Ghosh
H.C. Wainwright
H.C. Wainwright
$37
Buy
37.70%
Upside
Reiterated
08/25/26
ACADIA: EU Orphan Drug Launch Underscores Pricing Strength; Buy Rating and $37 Price Target Reaffirmed
BMO Capital Analyst forecast on GB:0A4W
Malcolm Hoffman
BMO Capital
BMO Capital
$36
Buy
33.98%
Upside
Reiterated
08/24/26
ACADIA: Buy Rating Reiterated as Daybue Momentum Builds and Key Pipeline Catalyst Nears; Price Target Maintained at $36
UBS Analyst forecast on GB:0A4W
Ashwani Verma
UBS
UBS
$45→$49
Buy
82.36%
Upside
Assigned
08/18/26
Acadia Pharmaceuticals price target raised to $49 from $45 at UBSAcadia Pharmaceuticals price target raised to $49 from $45 at UBS
Needham Analyst forecast on GB:0A4W
Ami Fadia
Needham
Needham
$38→$41
Buy
52.59%
Upside
Assigned
08/12/26
Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (NYSE: ELAN) and ACADIA Pharmaceuticals (NASDAQ: ACAD)
Canaccord Genuity Analyst forecast on GB:0A4W
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
$36
Buy
33.98%
Upside
Reiterated
08/12/26
ACADIA Pharmaceuticals: Buy Rating Reiterated on Undervalued Growth Story; $36 Price Target Unchanged
TD Cowen Analyst forecast on GB:0A4W
Ritu Baral
TD Cowen
TD Cowen
$37
Buy
37.70%
Upside
Assigned
08/05/26
ACADIA Pharmaceuticals: Strong Daybue Outperformance, STIX Uptake, and Raised FY26 Revenue Outlook Support Buy Rating
Citizens JMP Analyst forecast on GB:0A4W
Jason Butler
Citizens JMP
Citizens JMP
$35→$36
Buy
33.98%
Upside
Reiterated
08/05/26
Acadia Pharmaceuticals price target raised to $36 from $35 at CitizensAcadia Pharmaceuticals price target raised to $36 from $35 at Citizens
Stifel Nicolaus Analyst forecast on GB:0A4W
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$25
Hold
-6.96%
Downside
Reiterated
08/05/26
Stifel Nicolaus Sticks to Its Hold Rating for ACADIA Pharmaceuticals (ACAD)
Bank of America Securities Analyst forecast on GB:0A4W
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$30→$31
Buy
15.37%
Upside
Reiterated
08/05/26
Acadia Pharmaceuticals price target raised to $31 from $30 at BofAAcadia Pharmaceuticals price target raised to $31 from $30 at BofA
Oppenheimer Analyst forecast on GB:0A4W
Matthew Hershenhorn
Oppenheimer
Oppenheimer
$23→$25
Hold
-6.96%
Downside
Reiterated
08/05/26
Acadia Pharmaceuticals price target raised to $25 from $23 at OppenheimerAcadia Pharmaceuticals price target raised to $25 from $23 at Oppenheimer
Guggenheim Analyst forecast on GB:0A4W
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
―
Hold
―
Reiterated
08/04/26
Guggenheim Sticks to Its Hold Rating for ACADIA Pharmaceuticals (ACAD)
RBC Capital Analyst forecast on GB:0A4W
Brian Abrahams
RBC Capital
RBC Capital
$36→$37
Buy
37.70%
Upside
Assigned
08/04/26
Acadia Pharmaceuticals price target raised to $37 from $36 at RBC CapitalAcadia Pharmaceuticals price target raised to $37 from $36 at RBC Capital
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ODTXOdyssey Therapeutics, Inc.
BTSGBrightSpring Health Services, Inc.
GPCRStructure Therapeutics, Inc. Sponsored ADR
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering ACADIA Pharmaceuticals

3 Months
Brian AbrahamsRBC Capital
Success Rate
9/12 ratings generated profit
75%
Average Return
+7.03%
Copying Brian Abrahams's trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +7.03% per trade.
1 Year
Brian AbrahamsRBC Capital
Success Rate
12/12 ratings generated profit
100%
Average Return
+23.07%
Copying Brian Abrahams's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +23.07% per trade.
2 Years
Brian AbrahamsRBC Capital
Success Rate
12/12 ratings generated profit
100%
Average Return
+27.21%
Copying Brian Abrahams's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +27.21% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0A4W Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
4
7
6
6
1
Buy
15
10
13
16
29
Hold
8
4
4
6
9
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
27
21
23
28
39
In the current month, 0A4W has received 30 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. 0A4W average Analyst price target in the past 3 months is 35.47.
Each month's total comprises the sum of three months' worth of ratings.

0A4W Financial Forecast

0A4W Earnings Forecast

Next quarter’s earnings estimate for 0A4W is $0.20 with a range of $0.11 to $0.33. The previous quarter’s EPS was $0.18. 0A4W beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0A4W has Performed in-line its overall industry.
Next quarter’s earnings estimate for 0A4W is $0.20 with a range of $0.11 to $0.33. The previous quarter’s EPS was $0.18. 0A4W beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0A4W has Performed in-line its overall industry.

0A4W Sales Forecast

Next quarter’s sales forecast for 0A4W is $332.29M with a range of $325.00M to $341.88M. The previous quarter’s sales results were $307.96M. 0A4W beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0A4W has Performed in-line its overall industry.
Next quarter’s sales forecast for 0A4W is $332.29M with a range of $325.00M to $341.88M. The previous quarter’s sales results were $307.96M. 0A4W beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0A4W has Performed in-line its overall industry.

0A4W Stock Forecast FAQ

What is GB:0A4W’s average 12-month price target, according to analysts?
Based on analyst ratings, ACADIA Pharmaceuticals’s 12-month average price target is 35.47.
    What is GB:0A4W’s upside potential, based on the analysts’ average price target?
    ACADIA Pharmaceuticals has 31.99% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ACADIA Pharmaceuticals a Buy, Sell or Hold?
          ACADIA Pharmaceuticals has a consensus rating of Strong Buy, which is based on 12 buy ratings, 4 hold ratings and 0 sell ratings.
            What is ACADIA Pharmaceuticals’s share price target?
            The average share price target for ACADIA Pharmaceuticals is 35.47. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $49.00 ,and the lowest forecast is $25.00. The average share price target represents 31.99% Increase from the current price of $26.87.
              What do analysts say about ACADIA Pharmaceuticals?
              ACADIA Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.
                How can I buy shares of ACADIA Pharmaceuticals?
                To buy shares of GB:0A4W, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.